BRPI1007287B8 - composto de carboxamida, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica - Google Patents
composto de carboxamida, composição farmacêutica, e, uso de um composto ou de uma composição farmacêuticaInfo
- Publication number
- BRPI1007287B8 BRPI1007287B8 BRPI1007287A BRPI1007287A BRPI1007287B8 BR PI1007287 B8 BRPI1007287 B8 BR PI1007287B8 BR PI1007287 A BRPI1007287 A BR PI1007287A BR PI1007287 A BRPI1007287 A BR PI1007287A BR PI1007287 B8 BRPI1007287 B8 BR PI1007287B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- carboxamide
- disclosed
- conditions related
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- -1 carboxamide compound Chemical class 0.000 title abstract 3
- 101100321932 Rattus norvegicus Prkaa2 gene Proteins 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Emergency Medicine (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14798209P | 2009-01-28 | 2009-01-28 | |
| US61/147,982 | 2009-01-28 | ||
| PCT/US2010/022411 WO2010088392A1 (en) | 2009-01-28 | 2010-01-28 | Carboxamide compounds and methods for using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1007287B1 BRPI1007287B1 (pt) | 2021-03-09 |
| BRPI1007287B8 true BRPI1007287B8 (pt) | 2021-05-25 |
Family
ID=42061132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007287A BRPI1007287B8 (pt) | 2009-01-28 | 2010-01-28 | composto de carboxamida, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8362235B2 (https=) |
| EP (1) | EP2391616B1 (https=) |
| JP (1) | JP5658688B2 (https=) |
| KR (1) | KR101693061B1 (https=) |
| CN (1) | CN102365275B (https=) |
| AU (1) | AU2010208247B2 (https=) |
| BR (1) | BRPI1007287B8 (https=) |
| CA (1) | CA2750835C (https=) |
| EA (1) | EA022083B1 (https=) |
| ES (1) | ES2581678T3 (https=) |
| IL (1) | IL214203A (https=) |
| MX (1) | MX2011007639A (https=) |
| NZ (1) | NZ594556A (https=) |
| SG (1) | SG172974A1 (https=) |
| UA (1) | UA106600C2 (https=) |
| WO (1) | WO2010088392A1 (https=) |
| ZA (1) | ZA201105215B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010011288A (es) | 2008-04-23 | 2010-11-09 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida para el tratamiento de trastornos metabolicos. |
| WO2011123681A1 (en) | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| US9409884B2 (en) | 2012-02-01 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| WO2015048547A2 (en) * | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| US20160214967A1 (en) | 2013-09-30 | 2016-07-28 | The University Of Tokyo | Activator of adiponectin receptor |
| CN111787916B (zh) | 2018-01-11 | 2023-09-05 | 森陶鲁斯治疗公司 | 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂 |
| US12194023B2 (en) | 2018-11-29 | 2025-01-14 | The Research Foundation For The State University Of New York | Compositions and methods for modular control of bioorthogonal ligation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| KR100579792B1 (ko) * | 1998-05-13 | 2006-05-12 | 동화약품공업주식회사 | 신규 2,5-피리딘디카복실산 유도체 |
| AU2001287898A1 (en) * | 2000-09-22 | 2002-04-02 | Stephen Garland | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
| TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| US20070142369A1 (en) * | 2005-12-21 | 2007-06-21 | Margaret Van Heek | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
| DE602006021591D1 (de) | 2006-12-11 | 2011-06-09 | Genetics Co Inc | Aromatische 1,4-DI-Carboxylamide und deren Verwendung |
| CA2674237C (en) | 2006-12-28 | 2015-11-24 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| GB0706793D0 (en) * | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| BRPI0820171B8 (pt) | 2007-11-16 | 2021-05-25 | Rigel Pharmaceuticals Inc | compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos |
| CA2707047C (en) * | 2007-12-12 | 2017-11-28 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| MX2010011288A (es) * | 2008-04-23 | 2010-11-09 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida para el tratamiento de trastornos metabolicos. |
| WO2011123681A1 (en) | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
-
2010
- 2010-01-28 CN CN201080015415.6A patent/CN102365275B/zh not_active Expired - Fee Related
- 2010-01-28 BR BRPI1007287A patent/BRPI1007287B8/pt not_active IP Right Cessation
- 2010-01-28 MX MX2011007639A patent/MX2011007639A/es active IP Right Grant
- 2010-01-28 SG SG2011050861A patent/SG172974A1/en unknown
- 2010-01-28 NZ NZ594556A patent/NZ594556A/xx not_active IP Right Cessation
- 2010-01-28 ES ES10703206.2T patent/ES2581678T3/es active Active
- 2010-01-28 JP JP2011548297A patent/JP5658688B2/ja not_active Expired - Fee Related
- 2010-01-28 AU AU2010208247A patent/AU2010208247B2/en not_active Ceased
- 2010-01-28 EA EA201170979A patent/EA022083B1/ru not_active IP Right Cessation
- 2010-01-28 EP EP10703206.2A patent/EP2391616B1/en active Active
- 2010-01-28 KR KR1020117019811A patent/KR101693061B1/ko not_active Expired - Fee Related
- 2010-01-28 US US12/695,861 patent/US8362235B2/en not_active Expired - Fee Related
- 2010-01-28 UA UAA201110421A patent/UA106600C2/uk unknown
- 2010-01-28 CA CA2750835A patent/CA2750835C/en active Active
- 2010-01-28 WO PCT/US2010/022411 patent/WO2010088392A1/en not_active Ceased
-
2011
- 2011-07-14 ZA ZA2011/05215A patent/ZA201105215B/en unknown
- 2011-07-20 IL IL214203A patent/IL214203A/en active IP Right Grant
-
2012
- 2012-12-27 US US13/728,374 patent/US8846600B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8362235B2 (en) | 2013-01-29 |
| JP5658688B2 (ja) | 2015-01-28 |
| US20100190802A1 (en) | 2010-07-29 |
| EP2391616A1 (en) | 2011-12-07 |
| EA201170979A1 (ru) | 2012-02-28 |
| BRPI1007287B1 (pt) | 2021-03-09 |
| AU2010208247B2 (en) | 2015-06-18 |
| UA106600C2 (uk) | 2014-09-25 |
| CA2750835A1 (en) | 2010-08-05 |
| KR20110119755A (ko) | 2011-11-02 |
| CA2750835C (en) | 2018-09-04 |
| SG172974A1 (en) | 2011-08-29 |
| NZ594556A (en) | 2013-11-29 |
| IL214203A (en) | 2015-01-29 |
| ES2581678T3 (es) | 2016-09-06 |
| US20130131078A1 (en) | 2013-05-23 |
| WO2010088392A1 (en) | 2010-08-05 |
| EA022083B1 (ru) | 2015-10-30 |
| US8846600B2 (en) | 2014-09-30 |
| CN102365275B (zh) | 2014-09-24 |
| AU2010208247A1 (en) | 2011-08-11 |
| EP2391616B1 (en) | 2016-03-30 |
| ZA201105215B (en) | 2012-09-26 |
| HK1164860A1 (zh) | 2012-09-28 |
| IL214203A0 (en) | 2011-08-31 |
| CN102365275A (zh) | 2012-02-29 |
| MX2011007639A (es) | 2011-09-15 |
| JP2012516349A (ja) | 2012-07-19 |
| KR101693061B1 (ko) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1007287B8 (pt) | composto de carboxamida, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| BRPI0820171B8 (pt) | compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos | |
| CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
| CL2012001043A1 (es) | Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos. | |
| CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
| MX338707B (es) | Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos. | |
| DK2321321T3 (da) | Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister | |
| ECSP109917A (es) | Nuevos derivados de ácido azabifenilaminobenzoico | |
| CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
| DOP2007000078A (es) | Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| BR112013000537A2 (pt) | composição aquosa contendo bromexina | |
| ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
| CR20110318A (es) | Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos | |
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| CL2007001972A1 (es) | Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos. | |
| UY31922A (es) | Compuestos | |
| CL2012002706A1 (es) | Composicion farmaceutica termogelificante estabilizada compuesta por anestesicos locales con un ph de al menos el pka de dichos anestesicos, que comprende a) la forma basica de uno o mas anestesicos de tipo amida, b) 10 a 30% de un aceite de ricino polioxietilado, y c) al menos 15% de uno o mas tensioactivos; y su metodo de preparacion. | |
| CL2007001784A1 (es) | Compuestos derivados de benzoxazol de formula la, su composicion farmaceutica, metodo para medir in vivo depositos de amoloide empleando dicha composicion, y uso del compuesto la para preparar un medicamento, y compuesto de formula ib, y su uso como precursor en la preparacion de un compuesto marcado. | |
| ECSP088925A (es) | Nitrilos espirocíclicos como inhibidores de proteasa | |
| CL2011001026A1 (es) | Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato. | |
| CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. | |
| CL2011002463A1 (es) | Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica. | |
| ECSP088761A (es) | Nuevas combinaciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos | |
| AR062475A1 (es) | Combinaciones farmacologicas para el tratameinto de enfermedades de las vias aereas | |
| CL2007002103A1 (es) | Uso de pramipexol y un analgesico derivado del acido gamma aminobutirico para tratar el dolor; y composicion farmaceutica que los comprende. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2759 DE 21-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |